Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget

Health Economics

Volumn 14, Issue 8, 2005, Pages 793-803

  Zaric, Gregory S ^a   O'Brien, Bernie J ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Drug costs; Optimization; Pharmaceutical economics; Risk; Risk sharing

Indexed keywords

DRUG;

ARTICLE; BUDGET; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG FORMULARY; DRUG MANUFACTURE; DRUG QUALITY; MODEL; PRIORITY JOURNAL; PURCHASING; RISK MANAGEMENT;

COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; MODELS, ECONOMETRIC;

EID: 23244438337     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.976     Document Type: Article

References (14)

1. Department of Health. Cost Effective Provision of Disease Modifying Therapiesfor People with Multiple Sclerosis HSC 2002/004. Department of Health: London, 2002; 31.
2. Canadian Coordinating Office for Health Technology Assessment. Procedure for Common Drug Review, 2003. Canadian Coordinating Office for Health Technology Assessment, http://www.ccohta.ca/, accessed on 8 March, 2004.
3. Stinnett AA, Paltiel AD. Mathematical programming for the efficient allocation of health care resources. J Health Econ 1996; 15: 641-653.
4. Rentrak Corporation. Rentrak - Essential Business Intelligence, 1999. Rentrak Corporation, http://www.rentrak.com/bus_homevideo.php#revenue, accessed on 18 December 2003.
5. Patented Medicine Prices and Review Board. Patented Medicine Prices and Review Board, 2004. Government of Canada, http://www.pmprbcepmb.gc.ca/english, accessed on 30 June 2004.
6. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21(2): 89-103.
7. Dickson M, Redwood H. Pharmaceutical reference prices. How do they work in practice? Pharmacoeconomics 1998; 14(5): 471-479.
8. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997; 45(4): 535-544.
9. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997; 45(4): 523-533.
10. Mullins CD, Wang J. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. Pharmacoeconomics 2002; 20(1): 9-21.
11. Kane NM. Pharmaceutical cost containment and innovation in the United States. Health Policy 1997; 41(Suppl.): S71-S89.
12. Gencarelli DM. Medicaid prescription drug coverage: state efforts to control costs. NHPF Issue Brief 2003; 10(790): 1-17.
13. Curtiss FR. Methods of providing prescription drug benefits in health plans. Am J Hosp Pharm 1986; 43(10): 2428-2435.
14. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q 1993; 71(2): 217-252.